Bone Histomorphometry in Recombinant Human Erythropoietin-Treated Patients on Chronic Haemodialysis

2015 ◽  
pp. 127-135 ◽  
Author(s):  
Hans-Christof Schober ◽  
Roland Winkler ◽  
Reinhardt Schmidt ◽  
Klaus Abendroth ◽  
Horst Klinkmann
Keyword(s):  
Bone Histomorphometry ◽  
Recombinant Human Erythropoietin ◽  
Chronic Haemodialysis ◽  
Human Erythropoietin

scholarly journals The effect of erythropoietin treatment on left ventricular hypertrophy in haemodialysis patients

2003 ◽  
Vol 3 (4) ◽  
pp. 11-15 ◽  
Author(s):  
Senija Rašić ◽  
Indira Kulenović ◽  
Irfan Zulić ◽  
Azra Haračić ◽  
Mithat Čengić ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Recombinant Human Erythropoietin ◽  
Ventricular Hypertrophy ◽  
Significant Negative Correlation ◽  
Left Ventricular ◽  
Chronic Haemodialysis ◽  
Human Erythropoietin ◽  
Lv Mass ◽  
Erythropoietin Treatment ◽  
Anaemia Correction

Anaemia appears to play an important role in left ventricular (LV) enlargement in chronic kidney disease patients. The objective of this study was to evaluate LV echocardiography changes during anaemia correction with recombinant human erythropoietin(rHu-Epo) in chronic haemodialysis patients (HD pts) with signs of anaemia and LV hypertrophy (LVH). The study included 20 HD pts aged 39,6 +/- 5,3 yrs, with the same condition of HD treatment, anaemia and echocardiographically LVH verified. At the beginning of the rHu-Epo treatment haemoglobin (Hb) level was < 90 g/L and the target Hb level was 110 g/L. Echocardiography was performed at the beginning (baseline) and after six months of rHu-Epo treatment. LVH was defined as LV mass index >100 g/m2 in women and >131 g/m2 in men. We observed significant reduction of LV mass index (LVMI) (mean 26,4%, p=0.008), as well as LV volumen. There was a significant negative correlation between Hb level and LVMI with predictive LVMI reduction of 2,317 g/m2 for each 1g/L rising of mean Hb level. The results of the study confirm the importance of early anaemia correction in haemodialysis patients aimed to improve LV parameters.

Haemostatic Effects of Recombinant Human Erythropoietin in Chronic Haemodialysis Patients

1989 ◽  
Vol 61 (01) ◽  
pp. 117-121 ◽  
Author(s):  
Chris van Geet ◽  
Didier Hauglustaine ◽  
Luc Verresen ◽  
Marleen Vanrusselt ◽  
Jos Vermylen
Keyword(s):  
Platelet Count ◽  
Recombinant Human Erythropoietin ◽  
Bleeding Time ◽  
Chronic Haemodialysis ◽  
Recombinant Erythropoietin ◽  
The Third ◽  
Human Erythropoietin ◽  
Platelet Number ◽  
Almost All ◽  
And Function

SummaryRecombinant human erythropoietin was administered for up to 40 weeks to nine patients on chronic haemodialysis. From the third week of administration onwards, not only haemoglobin and haematocrit but also the platelet count rose, the latter, however, transiently. Subnormal platelet aggregation before therapy also improved transiently and in parallel with the erythropoietin dosage. The bleeding time normalized in almost all patients. There were no major side-effects. We conclude that recombinant erythropoietin improves haemostasis in chronic haemodialysis patients by increasing the haematocrit and in addition transiently enhances platelet number and function.

Recombinant Human Erythropoietin Increases Blood Pressure, Platelet Aggregability and Platelet Free Calcium Mobilisation in Uraemic Children: A Possible Link?

1990 ◽  
Vol 64 (01) ◽  
pp. 007-010 ◽  
Author(s):  
Chris Van Geet ◽  
Rita Van Damme-Lombaerts ◽  
Marleen Vanrusselt ◽  
An de MOl ◽  
Willy Proesmans ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Recombinant Human Erythropoietin ◽  
Intracellular Free Calcium ◽  
Free Calcium ◽  
Chronic Haemodialysis ◽  
Platelet Aggregability ◽  
Human Erythropoietin ◽  
Uraemic Children ◽  
Intracellular Free Calcium Concentration ◽  
Free Calcium Concentration

SummaryRecombinant human erythropoietin was administered to 10 uraemic children on chronic haemodialysis, all of whom responded by correcting their haemoglobin. In addition, they showed an increase in blood pressure; platelet aggregations, subnormal before therapy, improved during treatment. The intracellular free calcium concentration in platelets after thrombin stimulation also increased significantly during erythropoietin administration. We hypothesize that the effect of erythropoietin on platelet aggregability and on blood pressure may be due to an increase in the intracellular free calcium mobilisation in platelets and possibly in smooth muscle cells respectively.

Sign in / Sign up

Export Citation Format

Share Document